These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Daunorubicin. Results in childhood leukaemia.
    Author: Matthews RN, Colebatch JH.
    Journal: Arch Dis Child; 1972 Apr; 47(252):272-7. PubMed ID: 4502569.
    Abstract:
    Fifty children with acute leukaemia (44 lymphatic, 6 myeloid) were treated with daunorubicin. In 3 cases, it was given in courses of daily injections; in 47, single injections were given at 7- to 14-day intervals. On the latter (intermittent) regimen, in combination with prednisolone, a good response—complete, bone marrow, or clinical remission—occurred in 22 of 27 cases (81%) of `new' or previously untreated acute lymphoblastic leukaemia but in only 3 of 13 cases previously treated with other drugs. With acute myeloid leukaemia a good response occurred only when daunorubicin was given in combination with other cytotoxic drugs. The major side-effect was bone marrow depression with the related complications of haemorrhage and infection. Cardiotoxicity was not a problem; the cumulative total dose of daunorubicin did not exceed 26·8 mg/kg. This study indicates that intermittent dosage with 2-3 mg/kg at intervals of 7 to 14 days is as effective as, and no more toxic than, the courses of daily injections that have been commonly used.
    [Abstract] [Full Text] [Related] [New Search]